Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.36 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.36 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5286967 | 0.88 | GRIA1 (0.34) | GRIA1GRIA2GRIA3GRIA4MAOB | |
| SCHEMBL5280430 | 0.88 | GRIA1 (0.34) | GRIA1GRIA2GRIA3GRIA4MAOB | |
| SCHEMBL5281528 | 0.84 | MAOB (0.37) | GRIA1GRIA2GRIA3GRIA4MAOB | |
| SCHEMBL5278092 | 0.84 | MAOB (0.40) | GRIA1GRIA2GRIA3GRIA4MAOB | |
| SCHEMBL5284922 | 0.83 | GRIA1 (0.32) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5319341 | 0.83 | GRIA1 (0.32) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL5272708 | 0.83 | KDM4E (0.33) | GRIA1GRIA2GRIA3GRIA4PDE10A | |
| SCHEMBL5278035 | 0.81 | MAOB (0.44) | GRIA1GRIA2GRIA3GRIA4MAOB | |
| SCHEMBL5278361 | 0.81 | MAOB (0.51) | GRIA1GRIA2GRIA3GRIA4MAOB | |
| SCHEMBL5275179 | 0.78 | GRIA1 (0.36) | GRIA1GRIA2GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11679162-B2 | Anti-5T4 antibody-drug conjugate and use thereof | HANGZHOU ADCORIS BIOPHARMA CO., LTD. (CN) | 2023-06-20 | — | — | US | disclosed |
| US-20170281758-A1 | CALICHEAMICIN ANTIBODY DRUG CONJUGATES LINKING AN AMIDOACETYL GROUP TO A SUGAR MOIETY ON CALICHEAMICIN | SORRENTO THERAPEUTICS, INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170224835-A1 | Antibody Drug Conjugates | SORRENTO THERAPEUTICS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170190736-A1 | Antibody Drug Conjugates | SORRENTO THERAPEUTICS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| EP-1859781-A2 | Brightening and/or colouring agent with triazoles | Henkel Kommanditgesellschaft auf Aktien (DE) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11679162-B2 | Anti-5T4 antibody-drug conjugate and use thereof | SLC26A4, ABCC4, ABCB1 | GRIA1 1609/4885GRIA2 1587/4885GRIA3 1205/4885 |
| US-20170281758-A1 | CALICHEAMICIN ANTIBODY DRUG CONJUGATES LINKING AN AMIDOACETYL GROUP TO A SUGAR MOIETY ON CALICHEAMICIN | CALU, STT3A, STT3B | GRIA1 1447/4885GRIA2 2548/4885GRIA3 1910/4885 |
| US-20170190736-A1 | Antibody Drug Conjugates | STT3B, STT3A, HSD17B14 | GRIA1 2832/4885GRIA2 2881/4885GRIA3 1669/4885 |
| US-20170224835-A1 | Antibody Drug Conjugates | DARS1, CD38, AADAC | GRIA1 1733/4885GRIA2 1850/4885GRIA3 1734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.